Novel Therapy is Safe for Non-Hodgkin Lymphoma Patients, Roswell Park-Led Study Finds
December 08, 2020
December 08, 2020
BUFFALO, New York, Dec. 8 (TNSRes) -- The Roswell Park Comprehensive Cancer Center issued the following news release:
Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Dr. Hernandez-Ilizaliturri will present the team's findings today at the 62nd American Society of Hematology (ASH) Ann . . .
Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Dr. Hernandez-Ilizaliturri will present the team's findings today at the 62nd American Society of Hematology (ASH) Ann . . .